Geron (NASDAQ:GERN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Geron Corporation (NASDAQ:GERN) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.31 and traded as high as $1.36. Geron shares last traded at $1.32, with a volume of 5,333,184 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GERN. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Friday, October 31st. HC Wainwright reaffirmed a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. UBS Group reissued a “neutral” rating on shares of Geron in a report on Tuesday, December 9th. Finally, Needham & Company LLC lowered their price objective on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $2.75.

Geron Trading Down 1.5%

The company has a debt-to-equity ratio of 0.48, a quick ratio of 4.87 and a current ratio of 5.96. The company has a 50 day moving average of $1.24 and a two-hundred day moving average of $1.31. The stock has a market cap of $842.63 million, a PE ratio of -11.00 and a beta of 0.57.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Geron had a negative return on equity of 29.63% and a negative net margin of 43.61%.The company had revenue of $47.23 million for the quarter, compared to the consensus estimate of $55.24 million. Sell-side analysts anticipate that Geron Corporation will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Geron

Institutional investors have recently added to or reduced their stakes in the stock. Focus Partners Advisor Solutions LLC purchased a new stake in Geron in the 1st quarter worth $39,000. StoneCrest Wealth Management Inc. acquired a new stake in shares of Geron in the second quarter valued at about $35,000. Savant Capital LLC grew its position in shares of Geron by 73.8% in the second quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 11,074 shares during the period. Swiss Life Asset Management Ltd increased its stake in shares of Geron by 73.6% during the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 11,182 shares in the last quarter. Finally, Summit Financial Strategies Inc. acquired a new position in shares of Geron during the 2nd quarter worth about $38,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.